Abstract
Serine threonine protein kinase plays an important role in the cell growth, cell cycle regulation and development which shows a significant role in signal transduction pathway. In this study, a cationic peptide IE13 was derived from serine threonine protein kinase of a teleost fish and it was modified as IW13 by replacing the C-terminal residue with tryptophan. The anticancer potential of IE13 and IW13 was tested against three different types of cell lines HeLa (Human Cervical carcinoma cells), A549 (Human lung cancer cells) and MCF 7 (Human breast cancer cells) at different concentrations (300, 100, 30 and 10 µM) in semi logarithmic range. The results showed that the peptide IW13 showed EC50 of 92 µM for MCF 7, 102 µM for A549 and 85 µM for HeLa whereas, IE13 showed less growth inhibition on the tested cell lines. The flow cytometry study was conducted to demonstrate the cell cycle inhibition by the cationic peptide IW13 against HeLa cell line. Cytotoxicity studies of the cationic peptide showed no cytotoxicity against normal cell line (RAW 264.7). Tailoring of these properties was likely to be a key in safe and successful transfer of this peptide from laboratory experiments into clinical practice for pharmaceutical formulations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Peptide Research and Therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
